Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Total Valuation
Addex Therapeutics has a market cap or net worth of $8.96M. The enterprise value is $5.04M.
Market Cap$8.96M
Enterprise Value$5.04M
Share Statistics
Addex Therapeutics has 1,536,287 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,536,287
Owned by Insiders―
Owned by Institutions0.07%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -27.88%.
Return on Equity (ROE)0.73
Return on Assets (ROA)0.66
Return on Invested Capital (ROIC)-27.88%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee205.02K
Profits Per Employee3.53M
Employee Count2
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is 0.8. Addex Therapeutics’s PEG ratio is -0.00491.
PE Ratio0.8
PS Ratio12.67
PB Ratio0.54
Price to Fair Value0.54
Price to FCF-0.97
Price to Operating Cash Flow-1.61
PEG Ratio-0.00491
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 410.04K and earned 7.06M in profits. Earnings per share was 8.40.
Revenue410.04K
Gross Profit-444.26K
Operating Income-2.76M
Pretax Income-4.91M
Net Income7.06M
EBITDA-4.65M
Earnings Per Share (EPS)8.40
Cash Flow
In the last 12 months, operating cash flow was -1.44M and capital expenditures -1.27K, giving a free cash flow of -1.44M billion.
Operating Cash Flow-1.44M
Free Cash Flow-1.44M
Free Cash Flow per Share-0.94
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change-18.47%
50-Day Moving Average8.66
200-Day Moving Average8.17
Relative Strength Index (RSI)45.56
Average Volume (3m)45.37K
Important Dates
Addex Therapeutics upcoming earnings date is Nov 10, 2025, TBA (Confirmed).
Last Earnings DateSep 30, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 4.42, with Debt / Equity ratio of 0.48%
Current Ratio4.42
Quick Ratio4.42
Debt to Market Cap0.00
Net Debt to EBITDA0.71
Interest Coverage Ratio-776.78
Taxes
In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.35.
EV to Sales4.62
EV to EBITDA-0.41
EV to Free Cash Flow-0.35
EV to Operating Cash Flow-0.35
Balance Sheet
Addex Therapeutics has $2.30M in cash and marketable securities with $38.39K in debt, giving a net cash position of $2.26M billion.
Cash & Marketable Securities$2.30M
Total Debt$38.39K
Net Cash$2.26M
Net Cash Per Share$1.47
Tangible Book Value Per Share$11.84
Margins
Gross margin is 68.69%, with operating margin of -671.94%, and net profit margin of 1720.75%.
Gross Margin68.69%
Operating Margin-671.94%
Pretax Margin-1197.28%
Net Profit Margin1720.75%
EBITDA Margin-1132.98%
EBIT Margin-1196.41%
Analyst Forecast
The average price target for Addex Therapeutics is $8.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$8.50
Price Target Upside-0.23% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-80.31%
EPS Growth Forecast-293.92%